 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...3334353637383940414243...208209» |
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, Rubraca (rucaparib) / Pharma& Schweiz
Preclinical, Journal, BRCA Biomarker, PARP Biomarker: Bioanalytical assay for the quantification of rucaparib in rat plasma using UPLC-MS/MS: development, and validation for interaction with myricetin. (Pubmed Central) - Jun 10, 2025
The results of the drug-drug interaction (DDI) study showed that myricetin had no significant effect on the pharmacokinetic parameters of rucaparib, which indicating that the clinician did not need to adjust the dosage of rucaparib when it was used in combination. The UPLC-MS/MS method developed in this study was successfully used for the determination of the plasma concentrations of rucaparib orally administered in rats, which provided a reference for DDI studies and clinical pharmacokinetic studies of rucaparib.
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P2 trial: Dose-attenuated IST and Hetrombopag in Elderly (?65 Years) Patients With Severe Aplastic Anemia (clinicaltrials.gov) - Jun 9, 2025
P2, N=65, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report. (Pubmed Central) - Jun 9, 2025
The UPLC-MS/MS method developed in this study was successfully used for the determination of the plasma concentrations of rucaparib orally administered in rats, which provided a reference for DDI studies and clinical pharmacokinetic studies of rucaparib. ICLs in combination with antiangiogenic therapy may be a therapeutic option for patients with KRAS mutations in advanced non-small cell lung cancer with good persistence.
- | Journal: Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway. (Pubmed Central) - Jun 9, 2025
Notably, SP600125 and PD98059 contributed to the inhibition of EMT and EGFR/JNK/ERK pathway-related proteins by apatinib in sorafenib-resistant HCC. Apatinib potentially hindered the progression of sorafenib-resistant HCC by suppressing both EMT and the EGFR/JNK/ERK pathway.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia (clinicaltrials.gov) - Jun 9, 2025
P2, N=70, Recruiting, Sponsor: Peking Union Medical College Hospital
Apatinib potentially hindered the progression of sorafenib-resistant HCC by suppressing both EMT and the EGFR/JNK/ERK pathway. Trial completion date: Jun 2024 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
- | AiTan (rivoceranib) / HLB Bio Group
Biomarker, Journal: Tumor microenvironment-responsive nanoregulator CoMnMOF superparticles for enhanced microwave dynamic therapy via multi-pronged amplification of reactive oxygen species. (Pubmed Central) - Jun 8, 2025
To address these bottlenecks, we designed a multifunctional nanoregulator CoMnMOF@Apatinib@l-menthol@RBC-HA (denoted as CMALRH) to achieve enhanced MDT via a multi-pronged ROS amplification strategy...The experiments in vitro and in vivo confirmed the enhanced MDT in combination with microwave thermal therapy can successfully inhibit the proliferation of breast cancer. This TME based ROS amplification strategy provides an avenue for the development of remarkably high efficiency MDT and MW thermal therapy.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: AYVM to AYMM transition on HER2 exon 20 insertion induces TKI resistance in NSCLC. (Pubmed Central) - Jun 8, 2025
This TME based ROS amplification strategy provides an avenue for the development of remarkably high efficiency MDT and MW thermal therapy. Our findings unveil a new form of resistance-a secondary mutation superimposed on the original mutation-and offer insights into a potentially sequential strategy for overcoming resistance to pyrotinib.
- | Enrollment open: Neoadjuvant SNF Precision Therapy Phase III (clinicaltrials.gov) - Jun 6, 2025
P3, N=404, Recruiting, Sponsor: Fudan University
Our findings unveil a new form of resistance-a secondary mutation superimposed on the original mutation-and offer insights into a potentially sequential strategy for overcoming resistance to pyrotinib. Not yet recruiting --> Recruiting
- || Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge. (Pubmed Central) - Jun 6, 2025
Despite ongoing efforts to identify biomarkers that may guide treatment decisions, no validated prognostic or predictive biomarkers are currently available for SCLC. This review summarizes the present role of adebrelimab in SCLC and outlines novel strategies aimed to further improve survival outcome.
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov) - Jun 6, 2025
P1/2, N=100, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
This review summarizes the present role of adebrelimab in SCLC and outlines novel strategies aimed to further improve survival outcome. Not yet recruiting --> Recruiting
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The Impact of Tegileridine Fumarate Injection on Postoperative Urinary Retention Following Laparoscopic Hernia Repair in Elderly Patients: A Double-Blind, Randomized, Controlled Trial (EUDRACT) - Jun 6, 2025
P=N/A, N=220, Not yet recruiting, Sponsor: The First Affiliated Hospital of Shantou University Medical College; The First Affiliated Hospital of Shantou University Medical College
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A Single-Arm Exploratory Study of Adebrelimab Combined with Chemotherapy in the Treatment of Locally Recurrent Small Cell Lung Cancer (SCLC) (EUDRACT) - Jun 6, 2025
P=N/A, N=33, Recruiting, Sponsor: Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University
- | New trial, Checkpoint inhibition: A Single-Arm Clinical Trial Study to Evaluate the Efficacy and Safety of Vitamin K2 in Combination with an Immune Checkpoint Inhibitor for the Treatment of Advanced Second-Line Hepatocellular Carcinoma (EUDRACT) - Jun 6, 2025
P=N/A, N=43, Not yet recruiting, Sponsor: The Second Affiliated Hospital Zhejiang University School of Medicine; The Second Affiliated Hospital Zhejiang University School of Medicine
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial: A Single-Arm, Exploratory Clinical Study of Pyrotinib Combined with Dalpiciclib and Standard Endocrine Neoadjuvant Therapy in HR-Positive, HER2-Low-Expressing Breast Cancer (EUDRACT) - Jun 6, 2025
P=N/A, N=33, Not yet recruiting, Sponsor: The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New trial: A Prospective Cohort Study on Changes in the Foveal Avascular Zone in Patients with Type 2 Diabetes and Chronic Kidney Disease with or without Proteinuria Treated with Henggliflozin (EUDRACT) - Jun 6, 2025
P=N/A, N=100, Not yet recruiting, Sponsor: The First Central Hospital of Baoding; The First Central Hospital of Baoding
- || AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1 trial: Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Jun 6, 2025
P1, N=48, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Neoadjuvant Adebrelimab combined with Recatisibiumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A randomized,dual-cohort, exploratory phase 2 trial (EUDRACT) - Jun 6, 2025
P2, N=72, Not yet recruiting, Sponsor: Chinese PLA General Hospital; Chinese PLA General Hospital
- | RGL-270 / Shanghai Regenelead Therapies, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1 trial: An open, multi-center phase I clinical study to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of personalized new antigen RGL-270 single drug and combined with adebelimab in patients at high risk of recurrence after radical treatment of malignant solid tumors (EUDRACT) - Jun 6, 2025
P1, N=198, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Shanghai Regenelead Theraples,Co,Ltd.
- | Ivesa (firmonertinib) / Allist, ArriVent, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial, IO biomarker: BRIGHT-STAR: A Single-Arm, Exploratory Study of Adebrelimab Combined with Furmonertinib as First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression and Sensitive EGFR Mutationsre (EUDRACT) - Jun 5, 2025
P=N/A, N=36, Not yet recruiting, Sponsor: Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Camrelizumab plus apatinib for patients with recurrent or metastatic poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC): a prospective, open-label, phase II study (EUDRACT) - Jun 5, 2025
P=N/A, N=40, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Neoadjuvant pyrotinib plus trastuzumab combined with albumin-bound paclitaxel and carboplatin in patients with HER2+/HR+ early breast cancer: a single-arm multicenter phase 2 trail (EUDRACT) - Jun 5, 2025
P2, N=65, Recruiting, Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Phase II clinical study of irinotecan hydrochloride liposome Injection (II) combined with S-1 and camrelizumab in the treatment of patients with advanced metastatic esophageal squamous cell carcinoma who had failed previous treatments (EUDRACT) - Jun 5, 2025
P2, N=35, Not yet recruiting, Sponsor: Shandong Cancer Hospital and Institute, Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P4 trial, Real-world evidence: A multicenter real-world study on the treatment of prostate cancer with Rezvilutamide Tablets (EUDRACT) - Jun 5, 2025
P4, N=500, Not yet recruiting, Sponsor: QingHai University Affiliated Hospital; QingHai University Affiliated Hospital
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: A Multicenter, Randomized, Controlled Clinical Study of Hetrombopag Olamine versus Recombinant Human Thrombopoietin in the Treatment of Cancer Therapy Induced Thrombocytopenia (EUDRACT) - Jun 5, 2025
P=N/A, N=366, Not yet recruiting, Sponsor: Henan Cancer Hospital; Henan Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Study on the Efficacy and Safety of Interferon-? Combined with Camrelizumab in the Second-line Treatment of Advanced Squamous Cell Carcinoma (EUDRACT) - Jun 5, 2025
P=N/A, N=40, Not yet recruiting, Sponsor: Hefei Cancer Hospital, Chinese Academy of Sciences; Hefei Cancer Hospital, Chinese Academy of Sciences
- | Kerendia (finerenone) / Bayer
New P4 trial: A study on Efficacy and Safety of SGLT-2 Inhibitors Combined with Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (EUDRACT) - Jun 5, 2025
P4, N=1425, Not yet recruiting, Sponsor: The first medical center of Chinese PLA general hospital; Southeast University Affiliated Zhongda Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of SHR8554 on postoperative pain in Thoracoscopic Lung Surgery (EUDRACT) - Jun 5, 2025
P=N/A, N=256, Not yet recruiting, Sponsor: The First People
- | Jiataile (sacituzumab tirumotecan) / Merck (MSD), AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: An open, multicenter study on the treatment of recurrent and metastatic triple-negative breast cancer guided by cell surface protein typing (HIM) in triple-negative breast cancer (EUDRACT) - Jun 5, 2025
P=N/A, N=120, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial, Real-world evidence: Adebrelimab resumption after irAEs in solid tumors: a real-world study (EUDRACT) - Jun 5, 2025
P=N/A, N=500, Not yet recruiting, Sponsor: Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University
- | AiTan (rivoceranib) / HLB Bio Group
New P4 trial: Clinical study on the interaction between montmorillonite powder and apatinib mesylate tablets (EUDRACT) - Jun 5, 2025
P4, N=18, Not yet recruiting, Sponsor: Changzhou Cancer Hospital; Changzhou Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: PD-1 inhibitor plus induction chemotherapy combined with intensity-modulated radiotherapy versus induction chemotherapy combined with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma: an open-label, multicentre, randomised controlled phase III clinical trial (EUDRACT) - Jun 5, 2025
P3, N=438, Recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P4 trial: A Randomized, Open-Label Trial of Trastuzumab Combined with Pyrotinib and Taxanes (THPy) versus Trastuzumab Combined with Pertuzumab and Taxanes (THP) as First?Line Treatment for Advanced HER2?Positive Breast Cancer (EUDRACT) - Jun 5, 2025
P4, N=490, Not yet recruiting, Sponsor: Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial, IO biomarker: Adebrelimab Combined with Celecoxib and Chemotherapy as First-Line Treatment for PD-L1-Positive and HER2-Negative Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Exploratory Clinical Trial (EUDRACT) - Jun 5, 2025
P4, N=23, Not yet recruiting, Sponsor: The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Biocon, Biotech Pharma, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A single-arm, single-center, open, prospective phase II clinical study of camrelizumab combined with nimotuzumab and first-line chemoradiotherapy for the treatment of recurrent and metastatic cervical cancer (EUDRACT) - Jun 5, 2025
P2, N=42, Not yet recruiting, Sponsor: Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A single-arm, prospective study of adebrelimab in combination with chemotherapy in advanced first-line esophageal small cell carcinoma (EUDRACT) - Jun 5, 2025
P4, N=25, Recruiting, Sponsor: Anyang Cancer Hospital; Anyang Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New trial: Randomized, controlled, open label clinical study on the pharmacokinetic interaction between montmorillonite powder and apatinib mesylate tablets in human (EUDRACT) - Jun 5, 2025
P=N/A, N=18, Not yet recruiting, Sponsor: Changzhou Cancer (Fourth People's) Hospital; Changzhou Cancer (Fourth People's) Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Efficacy and safety study of Camrelizumab in combination with neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced cervical cancer (EUDRACT) - Jun 5, 2025
P2, N=33, Not yet recruiting, Sponsor: Lu'an People's Hospital; Lu'an People's Hospital
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New trial: Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial (EUDRACT) - Jun 5, 2025
P=N/A, N=150, Not yet recruiting, Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
- | Zykadia (ceritinib) / Novartis, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial: A Multicenter, Single-Arm Exploratory Study on the Combination of Pyrotinib and Ceritinib in the Treatment of Recurrent Solitary Fibrous Tumors of the Central Nervous System. (EUDRACT) - Jun 5, 2025
P=N/A, N=10, Not yet recruiting, Sponsor: Sanbo brain hospital capital medical university; Sanbo brain hospital capital medical university
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New trial: PCSK9 Inhibitor with Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial (EUDRACT) - Jun 5, 2025
P=N/A, N=300, Not yet recruiting, Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P4 trial: Preoperative single arm, multicenter, prospective clinical study of pyrotinib maleate tablets combined with albumin paclitaxel and trastuzumab in the treatment of HER2 positive early or locally advanced breast cancer (EUDRACT) - Jun 5, 2025
P4, N=40, Not yet recruiting, Sponsor: Huaihe Hospital of Henan University; Huaihe Hospital of Henan University
- | Focus V (anlotinib) / Advenchen, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A single-arm, exploratory phase II clinical study of adebrelimab combined with anlotinib and chemotherapy in the neoadjuvant treatment of resectable stage II-III non-small cell lung cancer (EUDRACT) - Jun 5, 2025
P2, N=44, Recruiting, Sponsor: Tianjin Medical University Cancer Institute & Hospital; Tianjin Medical University Cancer Institute & Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A Prospective, Single-Arm, Phase II Clinical Trial of Adebrelimab Combined with AG Regimen in Patients with Unresectable Locally Advanced or Metastatic Pancreatic Cancer (EUDRACT) - Jun 5, 2025
P2, N=46, Not yet recruiting, Sponsor: Fudan University Affiliated Cancer Hospital; Fudan University Affiliated Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A multi-cohort, phase II clinical study on the safety and efficacy of camrelizumab combined with apatinib as maintenance therapy in patients with inoperable stage III NSCLC after neoadjuvant chemoimmunotherapy combined with radiotherapy (EUDRACT) - Jun 5, 2025
P2, N=60, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group, iparomlimab (QL1604) / Qilu Pharma, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
New P4 trial: A Single-Arm, Open Phase II Clinical Trial of Iparomlimab and Tuvonralimab in Combination with Apatinib Mesylate and Capecitabine for Advanced Second-Line and Higher Esophageal Cancer (EUDRACT) - Jun 5, 2025
P4, N=30, Not yet recruiting, Sponsor: Taizhou People's Hospital; Taizhou People's Hospital
- | midazolam hydrochloride / Generic mfg.
New P4 trial: The safety and efficacy of remimazolam, midazolam and propofol for perioperative sedation during percutaneous tracheostomy in critically ill neurological patients (EUDRACT) - Jun 5, 2025
P4, N=40, Recruiting, Sponsor: Beijing tiantan hospital, capital medical university; Beijing tiantan hospital, capital medical university
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant chemotherapy plus camrelizumab and concurrent chemoradiotherapy for locally advanced nasopharygeal carcinoma (EUDRACT) - Jun 5, 2025
P2, N=62, Completed, Sponsor: Hui Zhou Municipal Central Hospital; Hui Zhou Municipal Central Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab-based therapy was used in solid tumors previously treated with PD-1 inhibitors: a single-arm, open, multicenter, exploratory clinical study (EUDRACT) - Jun 5, 2025
P2, N=20, Recruiting, Sponsor: Lianyungang First People's Hospital; Lianyungang First People's Hospital
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P4 trial: A randomized controlled study of Henagliflozin in type 2 diabetes mellitus with cardiac autonomic neuropathy (EUDRACT) - Jun 5, 2025
P4, N=94, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial, dMMR: PD-1 antibody carilizumab combined with apatinib for unresectable stage III and IV dMMR gastric cancer (EUDRACT) - Jun 5, 2025
P=N/A, N=20, Recruiting, Sponsor: Peking University Third Hospital; Peking University Third Hospital